Dr. Howard Verrico reports

SIRONA BIOCHEM SIGNS TERM SHEET FOR TFC-1067 WITH SKINCARE INDUSTRY LEADER RODAN + FIELDS

Sirona Biochem Corp. has signed a non-binding term sheet with Rodan + Fields LLC for the commercial sales of novel ingredient TFC-1067. This term sheet covers all material terms and conditions of a definitive agreement with San Francisco-based, industry-leading Rodan + Fields. The definitive agreement is expected to be signed in the third quarter of 2019.

The term sheet stipulates Sirona will become a manufacturer and supplier of TFC-1067 for use by Rodan + Fields on a non-exclusive basis in its current markets (United States, Canada and Australia) as well as future regions. Sirona has initiated preparations for manufacturing TFC-1067 to be in place near term for anticipated product launches. In addition to revenue from the sale of TFC-1067, a fee will be paid by Rodan + Fields on signing of the definitive agreement followed by milestone fees paid for each product launched by Rodan + Fields that incorporates Sirona's innovative skin-lightening agent, TFC-1067.

The term sheet incorporates establishing regular formal meetings between Sirona's scientists at TFChem and the scientists at the research department of Rodan + Fields. Future commercial opportunities based on the platform technology of Sirona Biochem will be explored. This term sheet is the result of extensive due diligence by Rodan + Fields spanning more than one year. This agreement is fitting for both Rodan + Fields and Sirona because of a mutual desire to deliver premium consumer products that are safe and effective.

Founded by Stanford-trained dermatologists, Dr. Katie Rodan and Dr. Kathy Fields, Rodan + Fields was launched with the mission of giving consumers the best skin of their lives and bring dermatology-inspired skin care to everyone. With clinic-quality skin care regimens and a powerful community of independent consultants, Rodan + Fields is the leading skin care brand in the United States and one of the fastest-growing industry disruptors in beauty.

Rodan + Fields has been ranked the No. 1 skin care brand in the U.S. and North America in 2018 by Euromonitor International Ltd., which publishes the world's most comprehensive market research on the skin care industry. Rodan + Fields has received several other accolades from Euromonitor, including the No. 1 premium acne brand in the U.S. and Canada and No. 1 premium body care brand in North America in 2018.

"After many years of developing TFC-1067 with the support of the French government and European Union in the Cosmetic Valley, France, we are excited to partner with skin care industry leader Rodan + Fields," reported Dr. Howard Verrico, chief executive officer of Sirona Biochem. "This marks an important milestone for Sirona Biochem. We highly value the successful due diligence of Rodan + Fields as further validation of our technology platform, in particular TFC-1067."

"We are committed to providing our consultant community and their consumers with products that feature cutting-edge technology that provide visible results. After an extensive search, we are pleased to partner with Sirona to leverage their new brightening agent in our products. With clinically proven effectiveness and an excellent safety profile, TFC-1067 will enable our products to improve the appearance of skin dullness, discolouration and uneven skin tone for a younger-looking complexion. We look forward to leveraging this excellent new ingredient in future product lines and working together to bring more of our life-changing skin care products to the market," said Simon Craw, senior director, research and development, business development, at Rodan + Fields.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules, with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments.

We seek Safe Harbor.